Topic

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Videos

In the concluding segment of a multi-part interview, Jason Bryant of ArisGlobal explains how human-in-the-loop and human-on-the-loop are both still relevant in AI implementation in pharma.

HITL and HOTL: An Air Traffic Control Analogy for Agentic AI

ArisGlobal’s Jason Bryant continues a video supplement to his series of articles on the adoption and implementation of AI agents.

Full Autonomy Is a ‘No-Go Zone’: Setting Parameters for Agentic AI in Pharma

In an expansion of his written three-part series for PharmTech, Jason Bryant of ArisGlobal explains the interplay between autonomy and accountability that is essential for AI agents assisting the pharmaceutical industry.

Autonomy Isn’t Binary: How Agentic AI Fits into the Pharma Landscape

Articles

In this look back at the year that was, in so many ways but in the bio/pharmaceutical industry especially, we remember 2025 as the point in time when AI declared it was here to stay.

The Year of AI: 2025’s Bio/pharma Upskilling Revolution

Machine learning tools are now moving from concept to validated applications, driving transformative shifts in bioanalysis, preclinical testing, and formulation optimization across the industry.

FAQ: Key AI Applications in Drug Development

As Thermo Fisher’s Jennifer Cannon explains in this first part of a two-part interview, the collaboration is intended to help improve the speed and success of drug development.

Thermo Fisher Launches OpenAI Partnership at CPHI Frankfurt 2025: Part One

Life sciences CEOs are boosting AI spending, focusing on workforce upskilling, and tackling ethical challenges to drive innovation and product development.

KPMG CEO Outlook: How Pharma Is Navigating AI, Regulatory Demands, and Supply Chain Risk

 is vice-president, Product Management for AI & Data at 

, based in London. A data science actuary, he has built his career in fintech and health-tech, and specializes in AI-powered, data-driven, yet human-centric product innovation. He previously led an AstraZeneca digital incubator and today remains on the board of a health charity, Scleroderma & Raynaud's UK (SRUK), which is dedicated to improving the lives of people affected by those conditions in the UK.

In the conclusion of this three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

What’s Reasonable to Expect from Agentic AI in Pharma? Part Three: Tapping Agentic AI’s Potential

In this continuation of a three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

What’s Reasonable to Expect from Agentic AI in Pharma? Part Two: Agentic AI’s Adoption in Life Sciences

Jennifer Markarian is a contributing editor for 

Advances in digital technologies offer effective data handling for bio/pharma manufacturing.

Data and Artificial Intelligence